11:37 AM EST - Revive Therapeutics Ltd. : Announced that it has signed a Memorandum of Understanding (“MOU”) with Attwill Medical Solutions Sterilflow, LP to establish AMS as a resource for clinical packaging and distribution for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. “We are pleased to engage in formal discussions with Attwill Medical to assist us in the clinical packaging and distribution for our Phase 3 clinical study in COVID-19, as they have the resources and capabilities to execute on a number of activities that are critical to large-scale clinical studies,” said Michael Frank, CEO of Revive. Revive Therapeutics Ltd.
shares C.RVV are trading up 8.93 percent at $0.31.
